Cargando…
Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis
Hereditary spherocytosis (HS) is a chronic hemolytic disorder caused by inherited defects in the red blood cell membrane. This study discusses the treatment strategy for the decline in hemoglobin level in three HS probands with moderately severe or severe hemolysis and summarizes the appropriate lab...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816590/ https://www.ncbi.nlm.nih.gov/pubmed/35126660 http://dx.doi.org/10.1155/2022/6228965 |
_version_ | 1784645470023319552 |
---|---|
author | Ma, Shiyue Tang, Lingjian Wu, Chaoli Tang, Hui Pu, Xue Niu, Jinhong |
author_facet | Ma, Shiyue Tang, Lingjian Wu, Chaoli Tang, Hui Pu, Xue Niu, Jinhong |
author_sort | Ma, Shiyue |
collection | PubMed |
description | Hereditary spherocytosis (HS) is a chronic hemolytic disorder caused by inherited defects in the red blood cell membrane. This study discusses the treatment strategy for the decline in hemoglobin level in three HS probands with moderately severe or severe hemolysis and summarizes the appropriate laboratory tests that help improve clinical management of blood transfusion in HS patients. Three probands who were diagnosed with HS in our hospital and their family members were included in this study. Clinical data of the three families were reviewed to summarize their hematopoietic characteristics. DNA from all family members of the 3 HS probands was amplified by polymerase chain reaction (PCR) and sequenced by the Sanger method to assess genetic relation for HS. Based on the sequencing results, the type of mutated membrane protein in each proband was analyzed using the eosin-5′-maleimide (EMA) binding test and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The hemoglobin level was reduced in all 3 probands after different levels of infection. The fluorescence of EMA-labeled red blood cell (RBC) was decreased. DNA sequencing showed that His54Pro, Leu1858Val, and 6531-12C>T compound heterozygous mutations were present in the SPTA1 gene of patient I-1, Arg344Gln and c.609+86G>A heterozygous mutations were present in the SLC4A1 gene of patient II-1, and Leu2032Pro homozygous mutation was present in the SPTB gene of patient III-1. SDS-PAGE results demonstrated that the concentration of band 3 was reduced in II-1, whereas the levels of the corresponding mutant proteins in the other probands were unchanged. The family members of the respective patients presented mutations in major genes causing HS. The Leu2032Pro mutation identified in patient III-1 is a new missense mutation of the SPTB gene in the Chinese population that has never been reported in literature previously. The presence or absence of acute or chronic infections is a critical deciding factor for the treatment and clinical management of HS patient via blood transfusion. For patients with infections, hemoglobin concentration can be restored once the infection is controlled, thus obviating the need for proper infection control before blood transfusion. |
format | Online Article Text |
id | pubmed-8816590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-88165902022-02-05 Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis Ma, Shiyue Tang, Lingjian Wu, Chaoli Tang, Hui Pu, Xue Niu, Jinhong Appl Bionics Biomech Research Article Hereditary spherocytosis (HS) is a chronic hemolytic disorder caused by inherited defects in the red blood cell membrane. This study discusses the treatment strategy for the decline in hemoglobin level in three HS probands with moderately severe or severe hemolysis and summarizes the appropriate laboratory tests that help improve clinical management of blood transfusion in HS patients. Three probands who were diagnosed with HS in our hospital and their family members were included in this study. Clinical data of the three families were reviewed to summarize their hematopoietic characteristics. DNA from all family members of the 3 HS probands was amplified by polymerase chain reaction (PCR) and sequenced by the Sanger method to assess genetic relation for HS. Based on the sequencing results, the type of mutated membrane protein in each proband was analyzed using the eosin-5′-maleimide (EMA) binding test and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The hemoglobin level was reduced in all 3 probands after different levels of infection. The fluorescence of EMA-labeled red blood cell (RBC) was decreased. DNA sequencing showed that His54Pro, Leu1858Val, and 6531-12C>T compound heterozygous mutations were present in the SPTA1 gene of patient I-1, Arg344Gln and c.609+86G>A heterozygous mutations were present in the SLC4A1 gene of patient II-1, and Leu2032Pro homozygous mutation was present in the SPTB gene of patient III-1. SDS-PAGE results demonstrated that the concentration of band 3 was reduced in II-1, whereas the levels of the corresponding mutant proteins in the other probands were unchanged. The family members of the respective patients presented mutations in major genes causing HS. The Leu2032Pro mutation identified in patient III-1 is a new missense mutation of the SPTB gene in the Chinese population that has never been reported in literature previously. The presence or absence of acute or chronic infections is a critical deciding factor for the treatment and clinical management of HS patient via blood transfusion. For patients with infections, hemoglobin concentration can be restored once the infection is controlled, thus obviating the need for proper infection control before blood transfusion. Hindawi 2022-01-28 /pmc/articles/PMC8816590/ /pubmed/35126660 http://dx.doi.org/10.1155/2022/6228965 Text en Copyright © 2022 Shiyue Ma et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ma, Shiyue Tang, Lingjian Wu, Chaoli Tang, Hui Pu, Xue Niu, Jinhong Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis |
title | Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis |
title_full | Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis |
title_fullStr | Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis |
title_full_unstemmed | Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis |
title_short | Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis |
title_sort | study on management of blood transfusion therapy in patients with hereditary spherocytosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816590/ https://www.ncbi.nlm.nih.gov/pubmed/35126660 http://dx.doi.org/10.1155/2022/6228965 |
work_keys_str_mv | AT mashiyue studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis AT tanglingjian studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis AT wuchaoli studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis AT tanghui studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis AT puxue studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis AT niujinhong studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis |